Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$190.90 USD
+0.18 (0.09%)
Updated Oct 13, 2025 03:59 PM ET
After-Market: $190.70 -0.20 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JNJ 190.90 +0.18(0.09%)
Will JNJ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
Markets Rebound Nicely Ahead of Q3 Earnings Season
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is J&J's MedTech Segment Set for Another Quarter of Growth?
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Other News for JNJ
Protagonist Therapeutics falls amid a report J&J deal price may be lower
Johnson & Johnson (JNJ) Q3 Earnings Preview: MedTech Focused Performance
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings Release as Cancer Therapy Gets Warning Label
Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings as Cancer Therapy Gets Warning Label